Auris Medical Stock Trading Higher After OligoPhore Technology Shows Tumor Inhibition In Animal Studies

Auris Medical Holding Ltd EARS has announced the publication of positive results from an in vivo study employing its OligoPhore technology in Adult T-cell Leukemia-Lymphoma (ATLL).
The article was published in Nanomaterials, an international peer-reviewed open-access journal.
Data demonstrated significant inhibition of tumor growth by siRNA knock-down of NF-κB utilizing the OligoPhore platform.
The study demonstrated rapid delivery of siRNA to the tumor and significant reduction of target mRNA and protein expression, which altered the natural history of subsequent tumor progression.
Tumor size, spleen size, and peripheral blood lymphocyte counts were significantly lower in treated mice than controls.
Tumor growth was reduced to near zero in the most aggressive tumors.
Further, the siRNA nanoparticles sensitized late-stage ATLL tumors to conventional chemotherapy with etoposide.
ATLL is a rare and aggressive type of non-Hodgkin's lymphoma of mature T cells caused by the Human T-cell Leukemia / Lymphotropic Virus type 1 (HTLV 1).
Price Action: EARS shares are up 12% at $3.72 during the market trading session on the last check Monday.